The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Mathew Cyriac & PACs
ZIMLAB · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On 13th March 2026, Mathew Cyriac along with his PACs (Elimath Advisors Pvt Ltd, Elizabeth Mathew, and Florintree Trinex LLP) carried out a series of share transactions in Zim Laboratories through open market trades and a preferential allotment. Before the transactions, the group's combined holding was 63,36,064 shares (11.84% of total share capital). After the transactions, their total holding rose to 1,03,48,766 shares, representing 19.34% of total share capital and 19.10% of diluted share capital, a net change of 7.50% from the last disclosure. The acquirers are explicitly classified as non-promoters. The total share capital of the company also expanded from 4,87,35,814 to 5,35,00,311 equity shares, partly due to the preferential allotment to Florintree Trinex LLP (47,64,497 shares at 8.91%).
This is a non-promoter acquisition that pushes the acquirer's stake to 19.34%, closing in on the 25% open offer trigger under SEBI Takeover Regulations. The 7.50% jump exceeds the 5% annual creeping acquisition limit, so an open offer to public shareholders may be triggered. Existing shareholders should monitor for any open offer announcement.